Showing results (31-40 of 800) with videos related to
Sort By:
Pageof 80
Plos Pathogens|November 2, 2018
HIV control: Is getting there the same as staying there?Philip Goulder, Steven G DeeksCurrent HIV/AIDS Reports|April 29, 2010
When to start antiretroviral therapyVivek Jain, Steven G DeeksThe Journal of Infectious Diseases|July 3, 2019
Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A SymposiumNir Eyal, Steven G DeeksJournal of Virology|May 30, 2006
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responsesSteven G Deeks, Becky Schweighardt, Terri Wrin, et al.AIDS (London, England)|November 12, 2014
Gut epithelial barrier and systemic inflammation during chronic HIV infectionMa Somsouk, Jacob D Estes, Claire Deleage, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2020
Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative ApproachMichael J Peluso, Lynda Dee, Shirley Shao, et al.HIV Research & Clinical Practice|August 6, 2026
Health-related quality of life trajectories during analytical treatment interruptions in HIV cure-related studies and the influence of depression, anxiety, and resilienceSteven Meanley, Ali Ahmed, Nadra E Lisha, et al.The Journal of Infectious Diseases|July 3, 2019
How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies?David M Margolis, Steven G DeeksTrends in Immunology|May 18, 2017
Signature of the Sleeper Cell: A Biomarker of HIV Latency RevealedSatish K Pillai, Steven G DeeksScience Translational Medicine|July 15, 2011
Drug effectiveness explained: the mathematics of antiviral agents for HIVAlan S Perelson, Steven G DeeksPageof 80